Small Molecule Therapeutics Delineating themTORKinasePathwayUsingaDual TORC 1 / 2 Inhibitor , AZD 8055 , in Multiple Myeloma

@inproceedings{Cirstea2014SmallMT,
  title={Small Molecule Therapeutics Delineating themTORKinasePathwayUsingaDual TORC 1 / 2 Inhibitor , AZD 8055 , in Multiple Myeloma},
  author={Diana Cirstea and Loredana Santo and Teru Hideshima and Homare Eda and Yuko Mishima and Neeharika Nemani and Anuj Mahindra and Andrew Yee and Gullu T Gorgun and Yiguo Hu and Hiroto Ohguchi and Rikio Suzuki and Francesca Cottini and Sylvie M. Guichard and Kenneth C. Anderson and Noopur Raje},
  year={2014}
}
Despite promising preclinical results with mTOR kinase inhibitors in multiple myeloma, resistance to these drugs may arise via feedback activation loops. This concern is especially true for insulin-like growth factor 1 receptor (IGF1R), because IGF1R signaling is downregulated by multiple AKT and mTOR feedback mechanisms. We have tested this hypothesis in multiple myeloma using the novel selective mTOR kinase inhibitorAZD8055.We evaluatedp-mTORS as the readout formTORC2/Akt activity… CONTINUE READING